Welcome to our dedicated page for DexCom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on DexCom stock.
DexCom, Inc. (DXCM) is a leading medical device company founded in 1999, specializing in continuous glucose monitoring (CGM) systems. These systems provide a significant advancement over traditional blood glucose meters, offering real-time glucose readings for diabetic patients. DexCom's innovative CGM technology empowers patients and clinicians to better manage diabetes, contributing to improved health outcomes.
DexCom's flagship products include the Dexcom G6 and the newly developed Dexcom G7 CGM systems. These devices offer features such as customizable alerts, seamless app integration, and data sharing capabilities. The company is also working on integrating their CGM systems with insulin pumps from Insulet and Tandem Diabetes Care, Inc., enabling automatic insulin delivery for more efficient diabetes management.
Recent achievements include the expansion into international markets and the continuous enhancement of their product lineup through research and development. Financially, DexCom has shown robust growth with increasing revenues and solid market performance, reflecting the growing demand for advanced diabetes management solutions.
The company has established strategic partnerships with key players in the medical device industry, further enhancing their market presence and technological capabilities. DexCom is committed to innovation, patient empowerment, and improving the quality of life for people with diabetes worldwide.
Dexcom, Inc. (NASDAQ:DXCM) has been certified as a Great Place to Work® in Canada for 2022-23, awarded by Great Place to Work Institute®. This recognition is based on employee feedback, with 92% expressing pride in their workplace. Senior Vice President Laura Endres emphasized the importance of their dedicated workforce in achieving this honor. The company is focused on enhancing employee experience and expanding its presence in Canada, aiming to improve diabetes management technology for Canadians.
DexCom, Inc. (NASDAQ:DXCM) will release its second quarter 2022 financial results after market close on July 28, 2022. A conference call is scheduled for 4:30 p.m. (Eastern Time) to discuss the results, which will be webcast. Investors can access the call by dialing (866) 374-5140 (US/Canada) or (404) 400-0571 (International), using confirmation number '24372094#'. DexCom is a leader in diabetes technology, aiming to empower users through innovative continuous glucose monitoring (CGM) systems.
Dexcom, a leader in real-time continuous glucose monitoring, celebrates Diabetes Awareness Week from June 13-19 by launching the 'No Pricks Parlour' on June 14 in London. This pop-up event promotes new NICE guidelines enhancing access to continuous glucose monitoring technology. Dexcom will be expanding its product line to include Dexcom ONE and Dexcom G7, improving diabetes management. The event aims to engage the community and raise awareness about the benefits of prick-free glucose monitoring, marking a significant step in diabetes care.
Dexcom is showcasing its expanded portfolio of real-time continuous glucose monitoring (CGM) systems at the 82nd Scientific Sessions of the American Diabetes Association in New Orleans from June 3-7, 2022. The portfolio includes Dexcom G6, G6 Pro, G7, and Dexcom ONE, emphasizing unparalleled accuracy and connectivity. Dexcom's advancements in automated insulin delivery systems position it as a leader in the iCGM market. Research presented at the conference highlights the effectiveness of Dexcom CGM in diabetes management compared to traditional methods.
Dexcom, Inc. (NASDAQ: DXCM) announced that its G6 continuous glucose monitoring (CGM) system is now eligible for public coverage in Prince Edward Island’s Diabetes Glucose Sensor Program for type 1 and type 2 diabetes patients aged two and older who are on multiple daily insulin injections or use insulin pumps. This expands access to advanced diabetes management technology, which has been proven to improve glycemic control and reduce long-term complications. The program joins other provinces in providing publicly funded coverage, aiming to enhance quality of life for Canadians living with diabetes.
DexCom, Inc. (NASDAQ:DXCM) has addressed recent media speculation regarding potential mergers and acquisitions. The company confirms it is currently not in active discussions about a merger transaction. This statement comes in the context of ongoing rumors and the approaching American Diabetes Association conference. DexCom's management emphasized their regular review of opportunities to enhance stockholder value but will not comment further on this matter unless circumstances change.
DexCom, Inc. (NASDAQ:DXCM) announced that Brice Bobzien, Senior Vice President of Finance, will present an update at the Piper Sandler Ophthalmology and Diabetes Symposium on May 25, 2022, at 1:00 p.m. EDT. The presentation will be accessible via webcast on the Dexcom Investor Relations website, where it will also be archived for future viewing.
Headquartered in San Diego, California, DexCom leads in diabetes care technology through innovative continuous glucose monitoring products.
DexCom, Inc. (NASDAQ:DXCM) has announced that Jereme Sylvain, Executive Vice President and CFO, will present updates at two upcoming investor conferences. The first is the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 5:40 PM (EST), and the second is the William Blair 42nd Annual Growth Stock Conference on June 8, 2022, at 5:00 PM (EST). Webcasts for these events will be available on the DexCom Investor Relations website and archived for future access.
DexCom announces an update regarding its first quarter 2022 earnings call, rescheduling it to start at 5:30 p.m. ET due to technical difficulties with the conference call provider. The link for the webcast will be available on the DexCom investor relations website and will be archived for future reference. Investors can listen to the call by dialing the provided numbers and using the confirmation number.
DexCom continues to focus on empowering diabetes management through innovative continuous glucose monitoring (CGM) systems, emphasizing its leadership in diabetes care technology.
DexCom, Inc. (Nasdaq: DXCM) reported a 25% revenue growth in Q1 2022, reaching $628.8 million. U.S. revenue rose 18% while international revenue surged 43%. GAAP operating income was $41.3 million (6.6% of revenue), down from the previous year. The company reaffirmed its 2022 revenue guidance of $2.82 - 2.94 billion and outlined strategic initiatives, including the limited launch of the Dexcom G7 in Europe and new market expansions. Cash reserves stood at $2.69 billion, providing strong financial flexibility.
FAQ
What is the current stock price of DexCom (DXCM)?
What is the market cap of DexCom (DXCM)?
What does DexCom, Inc. specialize in?
When was DexCom, Inc. founded?
What are some of DexCom's key products?
How do DexCom's CGM systems benefit diabetic patients?
What recent achievements has DexCom made?
How is DexCom integrating its CGM systems with other technologies?
What is the significance of DexCom's strategic partnerships?
What is DexCom's approach to innovation?
How does DexCom support the community?
What financial trends are seen in DexCom's performance?
